The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
If it goes any lower the company will be worthless
Upside on marketbeat of 250%
Bought these at 22p and think I've got a right bargain. If they go back up to 50p + doubled my money. Share tip last year by this is money and touched 80p. Marketbeat SP prediction around that price so if recovery in SP happens, happy days.
Any reason for today's jump in the SP
Reading MGCs twitter page they seem to be talking about their achievements, Cimetra being a success and record profits. The market however reacts negatively. At the moment there appears to be no demand for Cimetra. We were led to believe trials were advanced and to reduce hospital admissions, saving lives and governments $m's . If its as successful as they make out and Malta can produce 200,000 units a week and other companies are on standby to mass produce, why is it not being widely used. Led to believe india would approve it in 3 months. That appears to be pushed back another 3 months. Little news from trials in Amercia or Eastern Europe. Roby said in November that loads of good news coming and he's disappeared for the last two months with no further advancement. Makes me wonder whether he's been manipulating the market. If not, we're long overdue an update. News of record profits would normally cause the opposite reaction to the SP. It seems investors are losing faith and we need something to happen sooner rather than later to turn this around.
Some good news and an update on Cimetra progress in USA, India and Eastern Europe would be most welcome. After all the press releases from Roby telling shareholders how much good news was coming our way, he's gone very quiet. Makes me wonder what is happening and whether Roby has fed us all a load of spin. Need something positive please.
Everything is possible
If share price reaches 13.5 with 11m sales. What will SP rise to if sales rise to 1B.
Rich pipeline in the next few months
A substantial amount of newsflow is expected out of MGC Pharma over the next few months.
It’s currently completing a Phase 3 Israeli study on CimetrA, which should provide substantial clinical efficacy data in the first half of 2022.
In the US, the company plans to seek an FDA Emergency Use designation on CimetrA, and obtain significant near-term bulk orders from individual states using the US federal COVID-19 grant.
A Phase 2 in paediatric epilepsy trial of CBD-based drug CannEpil started in December 2021, with data possibly in 2H 2022.
In June last year, the drug became fully covered under Ireland’s Primary Care Reimbursement Service, meaning it will be free of charge for Irish patients prescribed the treatment.
CogniCann, which is currently being evaluated in a small Phase 2 trial for symptomatic relief of dementia, may produce initial data in the second half of 2022.
Meanwhile ArtemiC, the non-pharmaceutical food supplement version of CimetrA, is continuing to produce strong sales in Europe.
In November last year, MXC announced an approximately $1,000,000 ArtemiC order from its European partner, Swiss PharmaCan.
Sales to grow rapidly in the years ahead
Cannacord believes that CimetrA could reach peak sales above €150m, potentially in calendar 2023.
The fund manager also estimates peak sales for CannEpil could be above €600m after 2027, while CogniCann could have sales over €150m.
Based on these figures, Cannacord believes there is upside potential to 13.2 pence (24.5 cents) a share by late 2022 if trials progress as anticipated, and the data readouts are positive.
The valuation is also based on the assumption there will be a period of eight-year data exclusivity (2026-2033) for CannEpil and CogniCann as pharmaceutical products.
There may be a further two years of market exclusivity, but this is not assumed as cannabinoids are already available.
Currently, Cannacord has a speculative “buy” recommendation on MGC Pharma at GBP 7.2 pence (around 13.5c) a share.
At last some positive news. Time for some upward movement in the SP. Seems things are going to warm up nicely from this point.
Share price is balanced precariously waiting for an update. Let's hope its what MXC have led us to believe!!
Disappointing that there is still no news!! Perhaps a little more patience and we will get the news we are waiting for. Approval seems a painful process ??
Should be interesting to see the announcements heading our way. A lot of positive talk coming from MGC which seems to imply that SP is heading north very soon. It seems a fair few people on hear are loaded up and are set to do very nicely; myself included. If we get some big deals, who knows where this share price will end up. I do think it will grow by multiple times. Some of the deals could be colossal. Happy days. Oh what to spend our money on. New car? Lavish Holidays? What a great position we are all in :-)
£155k more buys today. If £747 late trade today is a buy, that is going to be really positive on SP in the morning. That alone is nearly X4 of total buys today. Exciting times!!
Do we know if 17:11 transaction of £747k was a buy or sell. Either way this could have a big impact on the SP early am tomorrow. Let's hope it a buy.
The doubters on here will soon eat humble pie. When the realisation sets in they have lost out on a massive opportunity. We'll be drinking champagne and they'll be having a knock at another company, drinking a cheap glass of lemonade, kicking themselves.....if only!!!
Really think this is heading north!!!!
If that doesn't indicate good news then I don't know what does.
Still massive for MGC. If permanent approval given, this is a game changer.
RNS Re:India was 02/09/2021. Approval to take 90 days. By my reckoning if approval on schedule we are due an update imminently. Brace yourselves for SP lift off if its the news we're all hoping for.
MGC don't have to manufacture Cimetra for Indian. It will be done for them but they will rake in the royalties xxxxx$ Medopharm Private Ltd (Medopharm), one of the leading manufacturers and exporters of pharmaceutical products in India, is managing the Emergency Use Authorisation process for CimetrA™ in India on MGC Pharma's behalf